Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics presented new Phase 3 Launch-HTN data for lorundrostat at ASN Kidney Week 2026, showing placebo-adjusted systolic blood pressure reductions of 9.6 mmHg in CKD patients and 12.2 mmHg in non-CKD patients at week 12. In CKD participants with baseline albuminuria, lorundrostat cut the urine albumin-to-creatinine ratio by 52.2% versus placebo, with a low hyperkalemia rate of 2.4%.
Key figures
- Drug Name
- lorundrostat
- Phase Of Trial
- Phase 3
- Pdufa date
- December 22, 2026
- Uacr reduction
- 52.2% vs placebo at week 12 (p<0.0001)
- Hyperkalemia rate
- 2.4% CKD, 0% non-CKD
- Sbp reduction ckd
- 9.6 mmHg placebo-adjusted at week 12 (p=0.0022)
- Sbp reduction non ckd
- 12.2 mmHg placebo-adjusted at week 12 (p<0.0001)
- Target sbp below 130 ckd
- 44% vs 18% placebo
- Target sbp below 130 non ckd
- 48% vs 22% placebo
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.